Status: Not yet recruiting
Stemchymal® for Polyglutamine Spinocerebellar Ataxia
The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.
Participants needed: 20
Trial details
Phase: Phase 2Age: 20-70Biological sex: AllType: InterventionalSponsor: Steminent US, Inc.Updated: May 2, 2024
Eligibility criteria
Subjects are with genotypically confirmed SCA3. [+5]
Subjects who have been enrolled in any kind of cell therapy within six months pr... [+9]